<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02119260</url>
  </required_header>
  <id_info>
    <org_study_id>117387</org_study_id>
    <nct_id>NCT02119260</nct_id>
  </id_info>
  <brief_title>A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients</brief_title>
  <official_title>A Sponsor Un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first administration of GSK2798745 in humans. This will be a sponsor
      un-blinded, placebo-controlled study to investigate the safety, tolerability,
      pharmacokinetics (PK), and pharmacodynamics (PD) of GSK2798745, given as single and repeat
      oral doses to healthy subjects and stable heart failure (HF) subjects. Approximately 28
      healthy subjects will be enrolled in the study cohorts (Cohort 1-3) involving single and
      repeat dose escalations of GSK2798745, while up to 24 stable heart failure subjects will be
      enrolled in Cohort 4 involving single and repeat dose administration of GSK2798745, with the
      dose selected based on data from healthy subject cohorts. This would be followed by
      enrollment of up to 8 subjects with heart failure in Cohort 5 involving repeat dose
      administration of GSK2798745. The study duration, including screening and follow-up, is not
      expected to exceed 17 weeks for subjects in the study (in any cohort).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2014</start_date>
  <completion_date type="Actual">December 25, 2016</completion_date>
  <primary_completion_date type="Actual">December 25, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by vital signs</measure>
    <time_frame>Up to 17 Weeks</time_frame>
    <description>Vital sign measurements will include systolic and diastolic blood pressure, heart rate, and respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by vital signs</measure>
    <time_frame>Up to 10 Weeks</time_frame>
    <description>Vital sign measurements will include systolic and diastolic blood pressure, heart rate, and respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by telemetry monitoring</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Continuous cardiac telemetry will be performed using a telemeter monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by telemetry monitoring</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Continuous cardiac telemetry will be performed using a telemeter monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by electrocardiogram (ECG)</measure>
    <time_frame>Up to 17 Weeks</time_frame>
    <description>Twelve-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be measured after resting in semi-supine position for 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by ECG</measure>
    <time_frame>Up to 10 Weeks</time_frame>
    <description>Twelve-lead ECGs will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals. ECGs will be measured after resting in semi-supine position for 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by clinical laboratory tests</measure>
    <time_frame>Up to 17 Weeks</time_frame>
    <description>Clinical laboratory tests include hematology, clinical chemistry, urinalysis and additional parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by clinical laboratory tests</measure>
    <time_frame>Up to 10 Weeks</time_frame>
    <description>Clinical laboratory tests include hematology, clinical chemistry, urinalysis and additional parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in healthy subjects as assessed by adverse events (AEs)</measure>
    <time_frame>Up to 17 Weeks</time_frame>
    <description>AEs will be collected from the start of study treatment and until the follow-up contact</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeat doses of GSK2798745 in stable HF subjects as assessed by AEs</measure>
    <time_frame>Up to 10 Weeks</time_frame>
    <description>AEs will be collected from the start of study treatment and until the follow-up contact</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of pharmacokinetic (PK) parameters following single and repeat dose administration of GSK2798745 in healthy subjects</measure>
    <time_frame>Days 1, 2, 3 and 4 for single dose; and Days 1, 2, 3, 4, 7, 10, 14, 15, 16 and 17 for repeat dose</time_frame>
    <description>From the plasma concentration-time data, the following PK parameters will be determined, as data permit: maximum observed plasma concentration (Cmax), time to Cmax (Tmax), area under the plasma concentration-time curve [AUC (0-t) and AUC (0-infinity)], and apparent terminal phase half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of PK parameters following single and repeat dose administration of GSK2798745 in stable HF subjects</measure>
    <time_frame>Days 1, 2, 3 and 4 for single dose; and Days 1, 2, 3, 4, 6, 8, 9 and 10 for repeat dose</time_frame>
    <description>From the plasma concentration-time data, the following PK parameters will be determined, as data permit: Cmax, Tmax, AUC (0-t) and AUC (0-infinity), and t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of PK parameters following single dose of GSK2798745 in fed and fasted state</measure>
    <time_frame>Days 1, 2, 3 and 4</time_frame>
    <description>Effect of food on PK will be assessed by comparing AUC and Cmax values in fed and fasted state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of PK parameters following single dose of GSK2798745 liquid or capsule formulations</measure>
    <time_frame>Days 1, 2, 3 and 4</time_frame>
    <description>From the plasma concentration-time data, the following PK parameters will be determined, as data permit: Cmax, Tmax, AUC (0-t) and AUC (0-infinity), and t1/2</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Oedema, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be randomized to 1 of 4 placebo-controlled dose sequences with 2 subjects in each sequence and each subject having four dose periods (3 active dose of GSK2798745 + 1 placebo dose). GSK2798745 will be administered in a liquid form (suspension or solution) in this cohort. In each treatment period, the subjects will be fasting from the prior midnight to four hours post-dose (Day 1).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Twelve subjects will receive GSK2798745 in three single-dose treatment periods in a fixed sequence. The actual dose-selected will be determined based on review of emerging safety and exposure data from Cohort 1. The dosing will be done in 3 study periods for investigating bioavailability and food effects. In Period 1, subjects will be fasting from midnight to four hours post-dose and will receive GSK2798745 in a liquid form (suspension or solution). In Period 2, subjects will be fasting from midnight to four hours post-dose and will receive a capsule formulation of GSK2798745. In Period 3, subjects will receive GSK2798745 capsule following a standard high fat/high calorie meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sixteen subjects will be randomized to 2 repeat dose cohorts with 8 subjects in each cohort in a ratio of 6:2 (treatments: placebo). Food intake timing will be determined based on data from Cohorts 1 and 2 (if Cohort 2 is conducted before Cohort 3). Doses will be administered once daily from Day 1 through Day14. Based on data from Cohort 1, the second dose in the repeat-dose period may be skipped to estimate the time invariance in PK. Dosing may be altered to twice daily based on the results obtained in the initial study cohort. Subjects will be fasted from midnight to 4 hours after dosing on Day 1 and Day 14 that entail serial PK sampling. Meal timings on other days will be based on previous cohort data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eighteen stable HF subjects will be randomized in this cohort with a treatment:placebo ratio of 1:1. If required, an additional number of subjects (up to 24 total) will be randomized. An additional separate dose group of approximately 18 to 24 subjects may be randomized to GSK2798745 or placebo to gain additional safety, tolerability,pharmacokinetic and pharmacodynamic information, if needed. The subjects will receive GSK2798745 in a single dose (at least the first 6 subjects) followed by a 7 -days repeat dose. Based on data from the cohorts 1, 2 and 3, the dose will be 2.4 mg (initial) in the first group utilizing the capsule formulation administered with or without food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight HF subjects will be randomized in this cohort with a treatment: placebo ratio of 3:1. This cohort will evaluate safety, pharmacokinetics, and lung permeability (DLco and DLno) in a boarder, more general population of patients with HF, NYHA Class II or III. Subjects will receive GSK2798745 or placebo (based on randomization) for 7 days. The dose will be 2.4 mg utilizing the capsule formulation administered with or without food. Subjects will remain in house from Day -1 until Day 4 and be fitted with a remote monitoring device; Day 5, 6 and 8 visits will be in home (on Days 5 and 6, they will receive study medication, collect samples for pharmacokinetic analysis, and assess vital signs); and subjects will return to the clinic for Day 7 visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2798745 solution</intervention_name>
    <description>Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2798745 suspension</intervention_name>
    <description>Aqueous suspension of GSK2798745 (&gt;=0.5 mg)</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2798745 capsule</intervention_name>
    <description>White Opaque granule filled capsules of GSK2798745 (&gt;=0.5 mg)</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <description>Clear, colourless solution of aqueous citrate buffer with 4% captisol</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo suspension</intervention_name>
    <description>Visually matching aqueous suspension of hypromellose acetate succinate powder</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Matching white opaque placebo blend filled capsule</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For Healthy Subject Cohorts (1-3):

          -  Male or female 18-75 years of age inclusive, at the time of signing the informed
             consent.

          -  Healthy as determined by a responsible and experienced physician, based on an
             evaluation including medical history, physical examination, laboratory tests and
             cardiac evaluation including ECG and echocardiogram. A subject with a clinical
             abnormality or laboratory parameter(s) which is/are not specifically listed in the
             inclusion or exclusion criteria, outside the reference range for the population being
             studied may be included only if the Investigator in consultation with the GSK Medical
             Monitor agree and document that the finding is unlikely to introduce additional risk
             factors and will not interfere with the study procedures.

          -  Body weight &gt;=50 kilogram (kg) and Body Mass Index (BMI) within the range 18-32
             kilogram/ square meter (kg/m^2) (inclusive).

          -  A female subject is eligible to participate if she is of Non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy for
             this definition, &quot;documented&quot; refers to the outcome of the Investigator's/designee's
             review of the subject's medical history for study eligibility, as obtained via a
             verbal interview with the subject or from the subject's medical records; or
             postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases a
             blood sample with simultaneous follicle stimulating hormone (FSH) &gt; 40
             milli-International Units per milliliter (mIU/mL) and estradiol &lt;40
             picogram/millilitre (pg/mL) [&lt;147 picomoles/liter (pmol/L)] is confirmatory.

          -  Male subjects with female partners of child-bearing potential must agree to use one of
             the contraception methods listed in the protocol. This criterion must be followed from
             the time of the first dose of study medication until 2 weeks post last dose.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Alanine transaminase (ALT), alkaline phosphatase and bilirubin &lt;= 1.5x Upper limit of
             normal (ULN) (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated
             and direct bilirubin &lt;35%).

          -  Based on averaged QTc values of triplicate ECGs obtained over a brief recording
             period: QTc &lt;450 milliseconds (msec); or QTc &lt;480 msec in subjects with Bundle Branch
             Block.

        For Heart Failure Subjects (Cohorts 4 and 5):

          -  Established diagnosis of mild or moderate heart failure of any aetiology with symptoms
             defined as corresponding to the New York Heart Association (NYHA) Class II or III on
             stable heart failure therapy for at least 1 month and was not hospitalized for HF for
             the last three months.

          -  Male or female 18 years or older, age inclusive, at the time of signing the informed
             consent.

          -  ALT, alkaline phosphatase and bilirubin &lt;=1.5xULN (isolated bilirubin &gt;1.5xULN is
             acceptable if bilirubin is fractionated and direct bilirubin &lt;35%).

          -  Based on averaged QTc values of triplicate ECGs obtained over a brief recording
             period: QTc &lt;450msec; or QTc &lt;480msec in subjects with Bundle Branch Block.

          -  Female subject is eligible to participate if she is of: Non-childbearing potential
             defined as pre-menopausal females with a documented tubal ligation or hysterectomy for
             this definition, &quot;documented&quot; refers to the outcome of the Investigator's/designee's
             review of the subject's medical history for study eligibility, as obtained via a
             verbal interview with the subject or from the subject's medical records; or
             postmenopausal defined as 12 months of spontaneous amenorrhea. In questionable cases a
             blood sample with simultaneous follicle stimulating hormone (FSH) &gt;40mIU/mL and
             estradiol &lt;40pg/mL (&lt;147pmol/L) is confirmatory.

          -  Male subjects with female partners of child-bearing potential must agree to use one of
             the contraception methods listed in the protocol. This criterion must be followed from
             the time of the first dose of study medication until 2 weeks post-last dose.

          -  Body weight &gt;=50kg and BMI within the range 18-40kg/m^2 (inclusive).

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

        Exclusion Criteria:

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  History of acute coronary syndromes (including unstable angina), coronary angioplasty,
             or stenting within the past 6 months.

          -  History of regular alcohol consumption within 6 months of the study defined as an
             average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is
             equivalent to 8 gram (g) of alcohol: a half-pint (approximately 240mL) of beer, 1
             glass (125mL) of wine or 1 (25mL) measure of spirits.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the Investigator and/or GSK
             Medical Monitor, contraindicates their participation.

          -  History of seizure disorder and or stroke within the last 5 years.

          -  Active ulcer disease or gastrointestinal (GI) bleeding.

          -  Current smokers (Cohorts 1-4 only).

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening.

          -  A positive pre-study drug/alcohol screen.

          -  A positive test for human immunodeficiency virus (HIV) antibody.

          -  A screening cardiac Troponin (cTn) level &gt;ULN.

          -  Baseline presence of severe aortic stenosis.

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 30 days, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  Left ventricular ejection fraction &lt;50 percent - (Healthy subjects only).

          -  Subject who, in the Investigator/designee's judgement, poses a significant suicide
             risk. Evidence of serious suicide risk may include any history of suicidal behaviour
             and/or any evidence of suicidal ideation on any questionnaires e.g., Type 4 or 5 on
             the Columbia Suicide Severity Rating Scale (C-SSRS) in the last 5 years.

        For Heart Failure Subjects (Cohort 4):

          -  History of known primary pulmonary disease requiring current medication or other
             therapy.

          -  Orthopnoea of sufficient severity to preclude supine scanning as determined at
             screening.

          -  Uncontrolled hypertension (resting systolic blood pressure [BP] &gt; 160 millimeters of
             mercury [mmHg] or resting diastolic BP &gt; 100 mmHg).

          -  Resting hypoxia while breathing room air (Peripheral capillary oxygen saturation
             [SpO2] &lt;88 percent).

          -  Estimated creatinine clearance (Cockcroft-Gault) &lt;40 mL/minute.

          -  Contraindication to magnetic resonance imaging (MRI) contrast agents.

          -  Contraindication for MRI scanning (as assessed by local MRI safety questionnaire),
             which includes but is not limited to: a. Intracranial aneurysm clips (except Sugita^Â®;
             trademark owned by Mizuho Ikakogyo Co.Ltd. Tokyo) or other metallic objects; b. Intra-
             orbital metal fragments that have not been removed; c. Pacemakers or other implanted
             cardiac rhythm management/monitoring devices and non-MR conditional heart valves; d.
             Inner ear implants; and e. History of claustrophobia.

        For Heart Failure Subjects (Cohort 5):

          -  Uncontrolled hypertension (resting SBP &gt;160 mmHg or reporting DBP &gt;100 mmHg).

          -  Resting hypoxia while breathing room air (SpO2 &lt;88 percent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2014</study_first_submitted>
  <study_first_submitted_qc>April 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2014</study_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First Time in Human</keyword>
  <keyword>TRPV4 inhibitor</keyword>
  <keyword>Heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Pulmonary Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 18, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

